|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 11.57 USD | +0.87% |
|
+2.84% | +6.83% |
| Apr. 18 | Viatris' Proposed Femoston, Duphaston UK Rights Divestment Being Considered, CMA Says | MT |
| Apr. 18 | UK Regulator to Consider Undertakings for Theramex-Viatris Deal | MT |
March 11 (Reuters) - The U.S. FDA has declined to approve Viatris and Mapi Pharma's once-a-month injection for the treatment of relapsing forms of multiple sclerosis, the companies said on Monday. (Reporting by Sriparna Roy and Sneha S K in Bengaluru; Editing by Pooja Desai)
Price
|
Change
|
5d. change
|
Capi.
| ||
|---|---|---|---|---|---|
| 2,686 PTS | +0.86% | +2.29% | - | ||
| 11.57 USD | +0.87% | +2.84% | 13.74B | ||
| 1st Jan change | Capi. | |
|---|---|---|
| +6.83% | 13.74B | |
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B |
VIATRIS INC. 
